scholarly journals Use of Denosumab in a Patient with Non–Small-Cell Lung Cancer and Severe Renal Function Impairment

2013 ◽  
Vol 8 (6) ◽  
pp. e52-e53 ◽  
Author(s):  
E. Govaerts ◽  
J. Vansteenkiste
Keyword(s):  
Lung Cancer ◽  
Renal Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Renal Function Impairment ◽  
Function Impairment

scholarly journals Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review

2011 ◽  
pp. 162-169
Author(s):  
Marcello Tiseo ◽  
Andrea Ardizzoni
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Scientific Question ◽  
Renal Function Impairment ◽  
Function Impairment ◽  
Equivalent Efficacy ◽  
Cisplatin Analog

Cisplatin has a pivotal role in the treatment of non-small cell lung cancer (NSCLC). However, it is associated with a number of serious and unpleasant side effects (nausea-vomiting, myelo-suppression, neuro-toxicity and renal function impairment). To overcome these limitations, most clinicians have turned towards the use of the cisplatin analog carboplatin, which is associated with a lower incidence of toxicity. Although carboplatin and cisplatin have a similar mechanism of action and pre-clinical spectrum of activity, it is still unclear whether they actually have the same clinical efficacy in all types of tumors. While for some tumors, such as ovarian cancer, equivalent efficacy has been convincingly proven, for others, such as germ cell and headneck tumors, there is some evidence that carboplatin is inferior to cisplatin. It has never been convincingly proven that carboplatin and cisplatin have the same efficacy in the treatment of NSCLC. This review provides an update of available evidences about this important scientific question.

Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed

2020 ◽  
Vol 76 (11) ◽  
pp. 1573-1580
Author(s):  
Louis Magali ◽  
Foucher Pascal ◽  
Aho Serge ◽  
Boulin Mathieu ◽  
Zouak Ayoube ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Renal Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Impaired Renal Function ◽  
Small Cell ◽  
Small Cell Lung

Effects of Gemcitabine on renal function in patients with non-small cell lung cancer

1998 ◽  
Vol 34 (1) ◽  
pp. 199-202 ◽  
Author(s):  
J.A Gietema ◽  
H.J.M Groen ◽  
S Meijer ◽  
E.F Smit
Keyword(s):  
Lung Cancer ◽  
Renal Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Acute Interstitial Nephritis in a Patient with Non-Small Cell Lung Cancer under Immunotherapy with Nivolumab

2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Panagiotis I. Georgianos ◽  
Vasilios Vaios ◽  
Eleni Leontaridou ◽  
Georgia Karayannopoulou ◽  
Triantafyllia Koletsa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Renal Function ◽  
Small Cell Lung Cancer ◽  
Interstitial Nephritis ◽  
Cell Lung Cancer ◽  
Acute Interstitial Nephritis ◽  
Small Cell ◽  
Close Monitoring ◽  
Partial Recovery ◽  
Small Cell Lung

Immune-checkpoint-inhibitors (ICPIs) represent a novel class of immunotherapy against several malignancies. These agents are associated with several “immune-mediated” adverse effects, but the reported renal toxicity of ICPIs is less well defined. We present the case of a 60-year-old man with a history of non-small cell lung cancer, who developed acute kidney injury (AKI) approximately 3.5 months after initiation of immunotherapy with nivolumab. Urinalysis revealed sterile pyuria, without microscopic hematuria or proteinuria. Immunological examination was negative. A renal biopsy showed severe interstitial inflammatory infiltration of T-cells, monocytes, and eosinophils without interstitial granulomas and normal appearance of glomeruli, indicating acute interstitial nephritis (AIN) as the cause of AKI. After a short-term course of corticosteroids and permanent nivolumab discontinuation, partial recovery of renal function was noted. AIN is a rare adverse effect of ICPIs that mandates the close monitoring of renal function in patients under immunotherapy with these agents.

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1990 ◽  
Vol 8 (9) ◽  
pp. 1556-1562 ◽  
Author(s):  
J Klastersky ◽  
J P Sculier ◽  
H Lacroix ◽  
G Dabouis ◽  
G Bureau ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Randomized Study ◽  
Working Party ◽  
Small Cell ◽  
Small Cell Lung ◽  
European Organization ◽  
Significant Difference ◽  
Function Impairment

The European Organization for Research and Treatment of Cancer (EORTC) Lung Cancer Working Party conducted a randomized trial comparing cisplatin (CDDP; 120 mg/m2, day 1) and carboplatin (CBDCA; 325 mg/m2, day 1) in combination with etoposide (VP16; 100 mg/m2, days 1, 2, and 3) in advanced non-small-cell lung cancer (NSCLC). Two hundred twenty-eight patients were eligible for survival and 202 assessable for response. We obtained 27 of 100 objective responses (ORs; 27%) in the CDDP arm and 16 of 102 (16%) in the CBDCA arm (P = .07). There was no significant difference in survival. Toxicity, consisting mainly of myelosuppression and renal function impairment, was significantly increased in the patients receiving the CDDP treatment. We conclude that CDDP plus VP16 was more active but also more toxic than CBDCA plus VP16 in advanced NSCLC.

Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non–small‐cell lung cancer: A retrospective cohort study (HYCIS‐XL)

2020 ◽  
Vol 45 (5) ◽  
pp. 1153-1158 ◽  
Author(s):  
Kelly L. Niggebrugge‐Mentink ◽  
Marieke M. Beex‐Oosterhuis ◽  
Peter G. J. Horst ◽  
Matthijs E. C. Poll ◽  
Hetty G. Dieleman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Renal Function ◽  
Cohort Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document